UroGen Pharma (URGN) announced positive five-year long-term extension study results for its ZUSDURI intravesical solution, demonstrating a median duration of response of 3.5 years in patients with low-grade intermediate-risk non-muscle invasive bladder cancer. These findings reinforce ZUSDURI's potential to provide significant, lasting event-free periods as a non-surgical alternative for recurrent patients, contributing to URGN shares trading up 1.51% pre-market.
UroGen Pharma Ltd. (URGN) has reported positive five-year long-term follow-up data from its Phase 2b OPTIMA II trial, significantly strengthening the clinical profile of its drug candidate, ZUSDURI. In a cohort of 17 patients with low-grade intermediate-risk non-muscle invasive bladder cancer who had an initial complete response, the median duration of response was an estimated 3.5 years. This result demonstrates a durable and lasting effect, building upon previously published 12-month data and reinforcing ZUSDURI's potential as a meaningful, non-surgical treatment alternative for recurrent patients who typically face repeated surgeries. The market has reacted favorably to this clinical de-risking, with URGN shares trading up 1.51% to $15.50 in the pre-market session, reflecting increased investor confidence in the asset's long-term viability.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment
